Long-term remissions after FCR chemoimmunotherapy in
previously untreated patients with CLL: updated results of
the CLL8 trial
by Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana
Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke,
Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl-Anton Kreuzer,
Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton,
Michael Kneba, Clemens-Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer,
and Michael Hallek
Blood
Volume 127(2):208-215
January 14, 2016
©2016 by American Society of Hematology
PFS and OS in both treatment arms.
Kirsten Fischer et al. Blood 2016;127:208-215
©2016 by American Society of Hematology
PFS and OS in both treatment arms and IGHV MUT/UNM patients.
Kirsten Fischer et al. Blood 2016;127:208-215
©2016 by American Society of Hematology
OS in genetic subgroups of IGHV MUT FCR patients (N = 107).
Kirsten Fischer et al. Blood 2016;127:208-215
©2016 by American Society of Hematology

RESULTATS 10 Km

15 Km

10 Km - athle